Third quarter in brief
Events after the end of the period
Financial summary
MSEK | Jul-Sep | Jan-Sep | Full-Year | |||||
2019 | 2018 | 2019 | 2018 | 2018 | ||||
Net sales | 0,9 | 4,7 | 7,5 | 15,2 | 20,1 | |||
Operating loss | -9,3 | -6,9 | -21,1 | -22,8 | -29,8 | |||
Loss after tax | -9,3 | -8,7 | -22,9 | -28,0 | -36,9 | |||
Earnings per share (SEK) | -0,06 | -0,06 | -0,16 | -0,21 | -0,27 | |||
Cash and cash equivalents (at close of period) | 69,9 | 36,0 | 25,6 |
For further information, please contact:
Helén Tuvesson, CEO Tel: +46 (0)46 19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46 19 20 00 |
The report is also available at www.activebiotech.com.
Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on November 14, 2019 at 08.30 a.m. CET.
Attachment